Company intelligence / Profile preview

Dexter

Lausanne, Vaud, Switzerlanddextergroup.com ↗

Ownership: Private
Development stage: Other

Overview

Dextera Biosciences is pioneering a new drug category—Synthetic D-proteins—that combine antibody-like specificity with small molecule-like distribution and oral bioavailability. Their preclinical pipeline targets major unmet needs in oncology and immunology by enabling sustained activity at interstitial targets with minimal immunogenicity. No clinical results have been published yet; all disclosed assets are preclinical or IND-enabling.

Therapeutic areas: GastroenterologyOncologyImmunology
Modalities: Synthetic D-protein therapy (a novel modality combining features of Antibody and Small molecule)Payload conjugate (for specific programs)Multi-specifics (multi-targeted therapies)
Industry: Biotech

Beyond the preview

Go deeper on Dexter.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dexter.

Explore the full profile